钠-葡萄糖协同转运蛋白-2抑制剂在射血分数保留的心力衰竭中的作用及机制研究进展

Research progress on the role and mechanisms of action of sodium-dependent glucose transporter 2 inhibitors in heart failure with preserved ejection fraction

钠-葡萄糖协同转运蛋白-2抑制剂(SGLT2i)是一种新型降糖药物,可通过抑制近端小管对葡萄糖的重吸收而降低血糖,广泛用于2型糖尿病的临床治疗。SGLT2i不仅可降低血糖,还具有多种心血管益处。随着多个大型临床随机对照试验结果的发布,SGLT2i在射血分数保留的心力衰竭(HFpEF)中的安全性和有效性已被证实。现就SGLT2i降低射血分数保留的心力衰竭患者心血管事件的风险其潜在机制的研究进行综述。

Sodium-dependent glucose transporter 2 inhibitors(SGLT2i)are a new class of glucose-lowering drugs,can reduce blood sugar by inhibiting the reabsorption of glucose at the proximal tubule and are widely used in clinical treatment of type 2 diabetes.SGLT2i can not only lower blood sugar,but also offer multiple cardiovascular benefits.Several large randomized controlled trials have confirmed the safety and efficacy of SGLT2i for heart failure with preserved ejection fraction(HFpEF).Herein,we present an overview on advances in SGLT2i for HFpEF.